Orphan Therapeutics Accelerator (OTXL)
Cambridge, MA
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (6)
○ EMA GMP
○ MHRA GMP
Quick Facts: Orphan Therapeutics Accelerator (OTXL)
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Cambridge, MA
- Modalities
- Gene Therapy (AAV), Lentiviral, Cell Therapy, Ex Vivo Gene Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Orphan Therapeutics Accelerator (OTXL)
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesGene Therapy (AAV), Lentiviral, Cell Therapy, Ex Vivo Gene Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (4 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press6 articles
Broad modality coverage (4 modalities)
Recent News 6 articles
Orphan Therapeutics Accelerator Announces Foundational Partnerships - Business Wire
Viralgen Joins Orphan Therapeutics Accelerator Clinical Development Network as a Manufacturing Partner to Advance Rare Disease Therapies - PR Newswire
ASCGT and OTXL partner for medicines for rare diseases - drugdiscoverytrends.com
Fondazione Telethon and Orphan Therapeutics Accelerator Sign Memorandum of Understanding to Pioneer Non-Profit Commercial Access Model for Ultra-Rare Disease Gene Therapy in the US - PR Newswire
AGC Biologics Joins Orphan Therapeutics Accelerator’s Clinical Development Network as a Manufacturing Partner to Advance Cell and Gene Therapies for Ultra-Rare Diseases - GlobeNewswire
Launch of CGTxchange to reactivate cell and gene therapy programs - BioWorld News
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral
OmniaBio
Hamilton, ON
Signal Score: 79.5
AAV, Lentiviral, CAR-T, Cell Therapy
bluebird bio Manufacturing
Durham, NC
Signal Score: 78.5
Lentiviral, Cell Therapy
Lonza
Basel, Switzerland
Signal Score: 78.2
AAV, Lentiviral, Cell Therapy, mRNA